Pomerantz Law Firm Warns Investors About Class Action Against Ardelyx, Inc. Over Securities Fraud
Investor Alert: Pomerantz Law Firm Issues Notice on Ardelyx, Inc. Class Action
The Pomerantz Law Firm has recently announced that a class action lawsuit has been initiated against Ardelyx, Inc. (NASDAQ: ARDX). This alert serves as an urgent notice for investors who suffered losses in their investments in Ardelyx. The firm encourages affected investors to reach out, especially those considering becoming Lead Plaintiffs in the ongoing litigation.
Understanding the Lawsuit
The class action revolves around allegations of securities fraud and other unlawful practices by Ardelyx and some of its executive officers or directors. Investors who bought or acquired Ardelyx securities during the specified Class Period have a critical deadline of November 16, 2026, to take action. This action might include filing the necessary papers to have themselves appointed as Lead Plaintiff in the case. Interested parties are invited to contact Danielle Peyton of Pomerantz LLP through email or phone for further guidance.
What Triggered the Action?
On August 6, 2026, Ardelyx made headlines with troubling news regarding its revenue guidance. The company announced a reduction in its full-year revenue expectations for its IBSRELA treatment, attributing the decrease to heightened payer utilization-management processes that have severely limited patient access and hindered new patient initiations. Additionally, the firm withdrew its long-term revenue guidance for XPHOZAH, citing
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.